You just read:

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA's Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia

News provided by

Rich Pharmaceuticals, Inc.

Feb 04, 2015, 09:45 ET